Fraction of Exhaled Nitric Oxide Is Elevated in Patients With Stable Chronic Obstructive Pulmonary Disease: A Meta-analysis
| Autor: | Shenglan Gong, Xiaoya Yang, Lingli Xie, Yin Pu, Hui Mao |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
medicine.medical_specialty
Respiratory Tract Diseases MEDLINE 030204 cardiovascular system & hematology Cochrane Library Nitric Oxide Pulmonary Disease Chronic Obstructive 03 medical and health sciences 0302 clinical medicine Internal medicine Eosinophilia Eosinophilic Humans Medicine 030212 general & internal medicine Asthma COPD business.industry Smoking General Medicine respiratory system medicine.disease Confidence interval respiratory tract diseases Breath Tests Case-Control Studies Meta-analysis Exhaled nitric oxide business |
| Zdroj: | The American Journal of the Medical Sciences. 360:166-175 |
| ISSN: | 0002-9629 |
| Popis: | Fraction of exhaled nitric oxide (FeNO) is a noninvasive indicator of eosinophilic airway inflammation and has been used for the diagnosis and treatment of asthma. The levels of FeNO are controversial in patients with stable chronic obstructive pulmonary disease (COPD). Accordingly, this study aimed to assess FeNO levels in patients with stable COPD.A search of the Medline, Embase, Web of Science, ClinicalTrials.gov and The Cochrane Library databases was performed in August 2019. The literature search was restricted to articles published in English. Studies were included if they reported data addressing FeNO levels in patients with stable COPD and healthy controls. Review Manager version 5.3 (The Nordic Cochrane Centre, The Cochrane Collaboration, Copenhagen, Denmark) was used for meta-analysis.A total of 19 studies were included. Analysis revealed that FeNO levels in patients with stable COPD were higher than those in the healthy control group (mean difference [MD] 2.49 [95% confidence interval {CI} 0.99-4.00]; P0.05), those in nonsmoking patients with stable COPD were higher than those in the healthy control group (MD 5.04 [95% CI 2.19-7.89]; P0.05) and those in smoking patients with stable COPD were not higher than those in the healthy control group (MD 0.30 [95% CI -2.81 to 3.41]; P = 0.85). FeNO measured using a chemiluminescence analyzer in nonsmoking patients with stable COPD was higher than those in the healthy control group (MD 4.84 [95% CI 1.83-7.86]; P0.05).Findings suggested that FeNO levels in patients with stable COPD were elevated, and that smokers exhibited decreased levels. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|